Case-Control Study on Narcolepsy Risk Factors Following Exposure to Anti-H1N1 Vaccines FRESH-PEF73060-en Antoine PARIENTE Case-Control Study on Narcolepsy Risk Factors Following Exposure to Anti-H1N1 Vaccines NarcoFluVF FRESH-PEF73060-en 73060 FRESH-PEF73060 Yves DAUVILLIERS Antoine PARIENTE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) UNIVERSITE DE BORDEAUX Epidemiology France Portal (PEF) AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE (ANSM) EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL null Yves;DAUVILLIERS Antoine;PARIENTE narcolepsy H1N1 influenza vaccines exposure Infectious disease medicine Neurology Narcolepsy Healthcare system determinants: Use of care Healthcare system determinants The main aim of the study was to determine the risk factors for narcolepsy; particularly focussing on the potential impact of influenza, H1N1 infection and vaccination (especially against the H1N1 influenza pandemic). As such, the study was able to contribute to the European study coordinated by the VAESCO consortium and received funding from the ECDC. The secondary aim was to compare the characteristics of exposed and unexposed cases. The potential impact of genetic susceptibility is not outlined in the final report (depending on the analyses that will potentially be carried out on stored samples). null France Individuals Patients population Male Female Child (6 to 12 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Cases were defined as patients diagnosed with narcolepsy; validated and classed according to the Brighton Classification Criteria by an approval committee; with an index date between 01/04/2009 and 30/04/2011, and where the onset of excessive daytime sleepiness (EDS) occurred before 31/12/2004. Controls: Patients of the same age, sex and treated at the same centre as the case subject. Treatment unrelated to narcolepsy or anti-H1N1 vaccination. Participant-reported health data Biological data Socio-demographic data Health event/morbidity Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Interview with the participant (including clinical) Observational Study Observational Study Case-control study Case: 85; Controls: 202 Completed study Restricted access Access on specific project only